RM2 - If we end up with a BP partner it's almost a given that between the BTD and a BP stepping up that the science would be viewed as almost valid which in theory should lift the share price. If there is yet one more BTD indication, that should also help the assent. You should have a number of opportunities to exit some of your holdings along the way at prices much higher than current. If you chose you can ride this pony to the end or lighten the load as we progress. iconoclast gave us some great information when he linked that article that said the average company at got BTD status sold for $8.3 billion. None of those drugs were either cardio or kidney drugs that I am aware of. The markets that ABL addresses, if a new P3 proves it, are enormous so I'm thinking we could be on the upper side of that average if it happens at all.

All IMO, dyodd

tada